Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

United States to end mpox emergency declaration

Published 12/02/2022, 04:09 PM
Updated 12/02/2022, 04:55 PM
© Reuters. FILE PHOTO: Workers sit outside of D.C. Health's first monkeypox vaccination clinic, which is administering the first Jynneos vaccine doses distributed in the U.S. capital, in Washington, U.S., June 28, 2022. REUTERS/Gavino Garay

(Reuters) -Mpox is expected to no longer be considered a public health emergency in the United States from Feb. 1, 2023, the U.S. health department said on Friday.

The months-long declaration was meant to tackle the largest-ever outbreak of cases in the country. The move signals that the crisis, which led to a spate of cases mostly among men who have sex with men, has come under control and would no longer require an emergency status meant to shore up funding and tools to fight the disease.

"Given the low number of cases today, HHS does not expect that it needs to renew the emergency declaration when it ends on January 31, 2023," U.S. Health Secretary Xavier Becerra said in a statement on Friday.

"But we won't take our foot off the gas – we will continue to monitor the case trends closely and encourage all at-risk individuals to get a free vaccine."

President Joe Biden's administration declared mpox a public health emergency in August after the country recorded over 6,000 cases and as the government came under pressure for its handling of the outbreak.

Cases have been in decline since mid-August in the country, the Centers for Disease Control and Prevention said last month.

The World Health Organization recently named the virus mpox to replace the older term monkeypox, citing concerns of stigma and racism associated with it.

WHO had said in November that the disease continues to represent a global health emergency, but also acknowledged progress made in the global response to the outbreak.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The WHO label, a "public health emergency of international concern (PHEIC)", is designed to trigger a coordinated international response and could unlock funding to collaborate on sharing vaccines and treatments.

The disease, which is endemic in parts of Africa, began spreading in Europe earlier this year before moving to the United States.

A rollout of Bavarian Nordic's Jynneos, the only approved monkeypox vaccine, and heightened awareness of the risks of the disease as well as increased immunity appear to have slowed the spread and helped bring cases under control.

Infectious disease experts say that years of financial neglect has left sexual health clinics - which are on the frontline of the current mpox response - ill-prepared to curb further spread.

Data from WHO shows that over 80,000 cases of mpox have been reported in nearly 100 countries since the outbreak started earlier this year. The number of cases have declined from the peak in August.

More than 29,000 cases have been reported in the United States in the outbreak this year, including two deaths, according to government data.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.